Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A7QN
|
|||
| Former ID |
DIB002916
|
|||
| Drug Name |
Moxisylyte
|
|||
| Synonyms |
Thymoxamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H25NO3
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C
|
|||
| InChI |
1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3
|
|||
| InChIKey |
VRYMTAVOXVTQEF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 54-32-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:94754
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-1D (ADRA1D) | Target Info | Modulator | [1], [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | Adrenoceptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.